nodes	percent_of_prediction	percent_of_DWPC	metapath
Amlexanox—IL3—Cytokines and Inflammatory Response—IL15—psoriatic arthritis	0.15	0.15	CbGpPWpGaD
Amlexanox—IL3—Cytokines and Inflammatory Response—IL13—psoriatic arthritis	0.105	0.105	CbGpPWpGaD
Amlexanox—IL3—Cytokines and Inflammatory Response—IL12B—psoriatic arthritis	0.0902	0.0902	CbGpPWpGaD
Amlexanox—S100A12—TAK1 activates NFkB by phosphorylation and activation of IKKs complex—NOD2—psoriatic arthritis	0.0644	0.0644	CbGpPWpGaD
Amlexanox—IL3—Cytokines and Inflammatory Response—HLA-DRB1—psoriatic arthritis	0.0531	0.0531	CbGpPWpGaD
Amlexanox—S100A12—TRAF6 Mediated Induction of proinflammatory cytokines—NOD2—psoriatic arthritis	0.0276	0.0276	CbGpPWpGaD
Amlexanox—IL3—Signaling by Interleukins—NOD2—psoriatic arthritis	0.0257	0.0257	CbGpPWpGaD
Amlexanox—IL3—Cytokines and Inflammatory Response—TNF—psoriatic arthritis	0.0251	0.0251	CbGpPWpGaD
Amlexanox—S100A12—MyD88 cascade initiated on plasma membrane—NOD2—psoriatic arthritis	0.025	0.025	CbGpPWpGaD
Amlexanox—S100A12—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—NOD2—psoriatic arthritis	0.0247	0.0247	CbGpPWpGaD
Amlexanox—S100A12—MyD88 dependent cascade initiated on endosome—NOD2—psoriatic arthritis	0.0243	0.0243	CbGpPWpGaD
Amlexanox—S100A12—Toll Like Receptor 9 (TLR9) Cascade—NOD2—psoriatic arthritis	0.0234	0.0234	CbGpPWpGaD
Amlexanox—S100A12—MyD88:Mal cascade initiated on plasma membrane—NOD2—psoriatic arthritis	0.023	0.023	CbGpPWpGaD
Amlexanox—S100A12—MyD88-independent cascade—NOD2—psoriatic arthritis	0.0221	0.0221	CbGpPWpGaD
Amlexanox—S100A12—Activated TLR4 signalling—NOD2—psoriatic arthritis	0.0199	0.0199	CbGpPWpGaD
Amlexanox—S100A12—Toll Like Receptor 4 (TLR4) Cascade—NOD2—psoriatic arthritis	0.0187	0.0187	CbGpPWpGaD
Amlexanox—S100A12—Toll-Like Receptors Cascades—NOD2—psoriatic arthritis	0.0167	0.0167	CbGpPWpGaD
Amlexanox—IL3—Cytokine Signaling in Immune system—HLA-C—psoriatic arthritis	0.0163	0.0163	CbGpPWpGaD
Amlexanox—IL3—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—psoriatic arthritis	0.0153	0.0153	CbGpPWpGaD
Amlexanox—S100A12—Innate Immune System—MEFV—psoriatic arthritis	0.0143	0.0143	CbGpPWpGaD
Amlexanox—FGF1—Downstream signaling events of B Cell Receptor (BCR)—REL—psoriatic arthritis	0.0123	0.0123	CbGpPWpGaD
Amlexanox—IL3—Cytokine Signaling in Immune system—NOD2—psoriatic arthritis	0.012	0.012	CbGpPWpGaD
Amlexanox—FGF1—B Cell Activation—REL—psoriatic arthritis	0.0109	0.0109	CbGpPWpGaD
Amlexanox—FGF1—DAP12 interactions—HLA-C—psoriatic arthritis	0.0108	0.0108	CbGpPWpGaD
Amlexanox—IL3—Immune System—MEFV—psoriatic arthritis	0.0104	0.0104	CbGpPWpGaD
Amlexanox—IL3—Cytokine Signaling in Immune system—HLA-B—psoriatic arthritis	0.00966	0.00966	CbGpPWpGaD
Amlexanox—S100A12—Immune System—MEFV—psoriatic arthritis	0.00835	0.00835	CbGpPWpGaD
Amlexanox—FGF1—Innate Immune System—MEFV—psoriatic arthritis	0.00819	0.00819	CbGpPWpGaD
Amlexanox—IL3—Cytokine Signaling in Immune system—HLA-DRB1—psoriatic arthritis	0.00817	0.00817	CbGpPWpGaD
Amlexanox—S100A12—Innate Immune System—HLA-C—psoriatic arthritis	0.00734	0.00734	CbGpPWpGaD
Amlexanox—FGF1—DAP12 interactions—HLA-B—psoriatic arthritis	0.00638	0.00638	CbGpPWpGaD
Amlexanox—IL3—Immune System—REL—psoriatic arthritis	0.0058	0.0058	CbGpPWpGaD
Amlexanox—S100A12—Innate Immune System—NOD2—psoriatic arthritis	0.0054	0.0054	CbGpPWpGaD
Amlexanox—IL3—Immune System—HLA-C—psoriatic arthritis	0.00533	0.00533	CbGpPWpGaD
Amlexanox—IL3—Integrated Pancreatic Cancer Pathway—TNF—psoriatic arthritis	0.00525	0.00525	CbGpPWpGaD
Amlexanox—IL3—Hemostasis—NOS2—psoriatic arthritis	0.00485	0.00485	CbGpPWpGaD
Amlexanox—FGF1—Immune System—MEFV—psoriatic arthritis	0.00477	0.00477	CbGpPWpGaD
Amlexanox—S100A12—Immune System—REL—psoriatic arthritis	0.00464	0.00464	CbGpPWpGaD
Amlexanox—FGF1—Adaptive Immune System—REL—psoriatic arthritis	0.00438	0.00438	CbGpPWpGaD
Amlexanox—S100A12—Innate Immune System—HLA-B—psoriatic arthritis	0.00434	0.00434	CbGpPWpGaD
Amlexanox—S100A12—Immune System—HLA-C—psoriatic arthritis	0.00427	0.00427	CbGpPWpGaD
Amlexanox—FGF1—Innate Immune System—HLA-C—psoriatic arthritis	0.00419	0.00419	CbGpPWpGaD
Amlexanox—FGF1—Adaptive Immune System—HLA-C—psoriatic arthritis	0.00403	0.00403	CbGpPWpGaD
Amlexanox—IL3—Immune System—NOD2—psoriatic arthritis	0.00392	0.00392	CbGpPWpGaD
Amlexanox—S100A12—Innate Immune System—CRP—psoriatic arthritis	0.00384	0.00384	CbGpPWpGaD
Amlexanox—IL3—Immune System—HLA-B—psoriatic arthritis	0.00315	0.00315	CbGpPWpGaD
Amlexanox—S100A12—Immune System—NOD2—psoriatic arthritis	0.00314	0.00314	CbGpPWpGaD
Amlexanox—FGF1—Innate Immune System—NOD2—psoriatic arthritis	0.00308	0.00308	CbGpPWpGaD
Amlexanox—IL3—Immune System—CRP—psoriatic arthritis	0.00279	0.00279	CbGpPWpGaD
Amlexanox—IL3—Immune System—HLA-DRB1—psoriatic arthritis	0.00267	0.00267	CbGpPWpGaD
Amlexanox—FGF1—Immune System—REL—psoriatic arthritis	0.00265	0.00265	CbGpPWpGaD
Amlexanox—S100A12—Immune System—HLA-B—psoriatic arthritis	0.00253	0.00253	CbGpPWpGaD
Amlexanox—FGF1—Innate Immune System—HLA-B—psoriatic arthritis	0.00248	0.00248	CbGpPWpGaD
Amlexanox—FGF1—Immune System—HLA-C—psoriatic arthritis	0.00244	0.00244	CbGpPWpGaD
Amlexanox—FGF1—Integrated Pancreatic Cancer Pathway—TNF—psoriatic arthritis	0.0024	0.0024	CbGpPWpGaD
Amlexanox—FGF1—Adaptive Immune System—HLA-B—psoriatic arthritis	0.00238	0.00238	CbGpPWpGaD
Amlexanox—S100A12—Immune System—CRP—psoriatic arthritis	0.00223	0.00223	CbGpPWpGaD
Amlexanox—FGF1—Innate Immune System—CRP—psoriatic arthritis	0.00219	0.00219	CbGpPWpGaD
Amlexanox—S100A12—Immune System—HLA-DRB1—psoriatic arthritis	0.00214	0.00214	CbGpPWpGaD
Amlexanox—FGF1—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	0.00202	0.00202	CbGpPWpGaD
Amlexanox—FGF1—Immune System—NOD2—psoriatic arthritis	0.0018	0.0018	CbGpPWpGaD
Amlexanox—FGF1—Immune System—HLA-B—psoriatic arthritis	0.00144	0.00144	CbGpPWpGaD
Amlexanox—FGF1—Immune System—CRP—psoriatic arthritis	0.00128	0.00128	CbGpPWpGaD
Amlexanox—FGF1—Immune System—HLA-DRB1—psoriatic arthritis	0.00122	0.00122	CbGpPWpGaD
Amlexanox—FGF1—Disease—NOS2—psoriatic arthritis	0.00108	0.00108	CbGpPWpGaD
